265 related articles for article (PubMed ID: 19671919)
21. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
22. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
[TBL] [Abstract][Full Text] [Related]
23. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity.
Janssens A; Tarantino M; Bird RJ; Mazzucconi MG; Boccia RV; Fernández MF; Kozak T; Steurer M; Boekhorst Pt; Dillingham K; Kreuzbauer G; Woodard P
Acta Haematol; 2015; 134(4):215-28. PubMed ID: 26066765
[TBL] [Abstract][Full Text] [Related]
24. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Al-Samkari H; Van Cott EM; Kuter DJ
Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
[TBL] [Abstract][Full Text] [Related]
25. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
[TBL] [Abstract][Full Text] [Related]
26. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
27. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
Grainger J; Bussel J; Tarantino M; Cooper N; Beam D; Despotovic J; Maschan A; Wang K; Eisen M; Bowers C
Blood Adv; 2023 Feb; 7(3):396-405. PubMed ID: 35413092
[TBL] [Abstract][Full Text] [Related]
28. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
[TBL] [Abstract][Full Text] [Related]
29. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
[TBL] [Abstract][Full Text] [Related]
30. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE; Rose MJ
Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Brynes RK; Orazi A; Theodore D; Burgess P; Bailey CK; Thein MM; Bakshi KK
Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
[TBL] [Abstract][Full Text] [Related]
32. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.
Boiocchi L; Orazi A; Ghanima W; Arabadjief M; Bussel JB; Geyer JT
Mod Pathol; 2012 Jan; 25(1):65-74. PubMed ID: 21841770
[TBL] [Abstract][Full Text] [Related]
33. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
34. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
35. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
Doobaree IU; Newland A; McDonald V; Nandigam R; Mensah L; Leroy S; Seesaghur A; Patel H; Wetten S; Provan D
Eur J Haematol; 2019 May; 102(5):416-423. PubMed ID: 30758874
[TBL] [Abstract][Full Text] [Related]
36. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
37. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
[TBL] [Abstract][Full Text] [Related]
38. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
Kuter DJ; Bussel JB; Newland A; Baker RI; Lyons RM; Wasser J; Viallard JF; Macik G; Rummel M; Nie K; Jun S
Br J Haematol; 2013 May; 161(3):411-23. PubMed ID: 23432528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
